

Leukaemia Section

Short Communication

del(21)(q21q22) USP16/RUNX1

Marie-Joëlle Mozziconacci, Daniel Birnbaum

Departement de Biopathologie et Laboratoire d'Oncologie Moleculaire, Centre de Recherche en Cancerologie de Marseille, UMR1068 Inserm, Institut Paoli-Calmettes 27 Boulevard Lei Roure 13009 Marseille, France (MJM), Laboratoire d'Oncologie Moleculaire, Centre de Recherche en Cancerologie de Marseille, UMR1068 Inserm, Institut Paoli-Calmettes 27 Boulevard Lei Roure 13009 Marseille, France (DB)

Published in Atlas Database: October 2013

Online updated version : <http://AtlasGeneticsOncology.org/Anomalies/del21q21q22ID1607.html>
DOI: 10.4267/2042/53541

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2014 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Abstract

Review on del(21)(q21q22) USP16/RUNX1, with data on clinics, and the genes implicated.

Identity

Note

Microdeletions and inversion at 21q21 leading to USP16-RUNX1 fusion in CMML.

Clinics and pathology

Disease

AML-M4

Note

Male patient 74 year-old.

Phenotype/cell stem origin

CD4, 11b, 13, 14, 15, 33, 36, 56, 117 positive.

Etiology

Thrombocytopenia 2 years before, chronic myelomonocytic leukemia (CMML) 1 year before.

Epidemiology

Toxic exposure at work (oil by-products).

Clinics

Bilateral inguinal ADP.

No hepatosplenomegaly.

No involvement of central nervous system.

Tricytopenia: WBC $2.9 \times 10^9/L$, Hb 10.7g/dl and platelets $12 \times 10^9/L$.

Cytology

Hypercellular bone marrow, rare megakaryocytes. 72% blast cells.

AML-M4 with no morphologic arguments for a secondary leukemia.

Treatment

Induction Idarubicin/Aracytin. GFM Azacytidin protocol.

Evolution

Survival 2.5 years.

Cytogenetics

Note

RHG banding on bone marrow.

Cytogenetics morphological

47,XY,+8[11]/46,XY[9]

Cytogenetics molecular

ND

Genes involved and proteins

USP16

Location

21q21.3

RUNX1

Location

21q22.12




Figure 1A: Genomic rearrangement involving USP16 and RUNX1 genes in a CMML. Profile of chromosome 21 shows regional deletions in 21q21.3 and 21q22.12. Arrowheads point to USP16 and RUNX1 genes targeted by transition profiles located in these respective regions. **Figure 1B:** USP16-RUNX1 rearrangement. Inversion of the 21q21.3-q22.12 region and generation of USP16-RUNX1 gene fusion. Organization of chromosomal region 21q21.3-q22.12 with the location of the breakpoints (BP) and deleted regions. The potential gene breakages and deleted regions were refined to an interval (vertical arrows and grey boxes, respectively) defined by aCGH. Breakpoints BP1 and BP3 targeting USP16 and RUNX1 are associated with deletions defined by intervals [BP1-BP2] and [BP3-BP4]. The USP16-RUNX1 gene fusion characterized by RT-PCR is explained by the inversion of the central interval [BP2-BP3]. ATG codons are in exon 2 (ex 2) and exon 1 (ex 1) of USP16 and RUNX1, respectively. The event fuses exon 1 of USP16 to exon 5 of RUNX1 not preserving the canonical ATG.

Result of the chromosomal anomaly

Hybrid gene

Note

The aCGH profile (244K CGH Microarrays Hu-244A, Agilent Technologies, Massy, France) showed two losses at 21q21.3 and q22.12 of about 1.04 Mb and 0.82 Mb, respectively (Figure 1A). They spanned the 3' part of USP16, including exons 2 to 19, and the 5' part of RUNX1 (including exons 1 to 4), respectively.

Description

A cryptic inv(21)(q21q22) associated with a microdeletion at one of the breakpoints, and a fusion involving RUNX1 and USP16 (encoding a de-ubiquitinating enzyme).

This was confirmed by nested PCR amplification of reverse-transcribed RNA from the patient's BM cells, which detected a 245 bp-long USP16-RUNX1 transcript.

No reciprocal transcript was detected. Sequence analysis showed that the result of the inversion/fusion generated a chimeric USP16-RUNX1 transcript.

Transcript

The USP16-RUNX1 fusion transcript did not have an open reading frame using the canonical start codons of USP16 or RUNX1.

However, multiple ATG codons through exons 5 to 7 of the fused RUNX1 sequence could be used as new start codons and generate truncated RUNX1 proteins.

The break/fusion was not present in the germline since we did not find the USP16-RUNX1 transcript in buccal smear cells of the patient.

Detection

The 21q inversion was not detectable by karyotyping and would not have been detected by array-CGH if not for the interstitial microdeletion.

To be noted

We found a similar USP16-RUNX1 fusion without microdeletion in another case of CMML, with the same consequences on transcript and putative proteins.

References

Gelsi-Boyer V, Trouplin V, Adélaïde J, Aceto N, Remy V, Pinson S, Houdayer C, Arnoulet C, Sainty D, Bentires-Alj M, Olschwang S, Vey N, Mozziconacci MJ, Birnbaum D, Chaffanet M. Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. *BMC Cancer*. 2008 Oct 16;8:299

This article should be referenced as such:

Mozziconacci MJ, Birnbaum D. del(21)(q21q22) USP16/RUNX1. *Atlas Genet Cytogenet Oncol Haematol*. 2014; 18(4):279-281.
